Sudarshan Pharma Industries (543828) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 were approved, with auditors issuing an unmodified opinion on both sets of results.

• The company voluntarily adopted Indian Accounting Standards (Ind AS) from April 1, 2025, with a transition date of April 1, 2024.

Financial highlights

• Standalone revenue from operations for FY26 was ₹66,749.85 lakhs, up from ₹50,249.34 lakhs in FY25; consolidated revenue was ₹70,305.65 lakhs, up from ₹50,503.52 lakhs year-over-year.

• Standalone net profit for FY26 was ₹2,198.16 lakhs, up from ₹1,402.16 lakhs in FY25; consolidated net profit was ₹2,337.17 lakhs, up from ₹1,496.52 lakhs year-over-year.

• Standalone EPS for FY26 was ₹0.91 (basic), up from ₹0.58; consolidated EPS was ₹0.97 (basic), up from ₹0.62 year-over-year.

• Total comprehensive income for FY26 was ₹2,199.69 lakhs (standalone) and ₹2,342.22 lakhs (consolidated).

Outlook and guidance

• The company is pursuing fund-raising through Foreign Currency Convertible Bonds (FCCB) up to ₹1,500 crores, with regulatory approvals in place and a renewed application submitted after an initial attempt did not materialize.